Tumor biology and access to care and metastatic breast cancer outcomes
Matthew R. Dunn, Sarah C. Van Alsten, Marc A. Emerson, Katherine Reeder-Hayes, Terry Hyslop, Melissa A. Troester · 2025
Read Tumor biology and access to care and metastatic breast cancer outcomes by Matthew R. Dunn, Sarah C. Van Alsten, Marc A. Emerson, Katherine Reeder-Hayes, Terry Hyslop, Melissa A. Troester (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12743023.txt.
Description
Matthew Dunn and co-authors asked how much of the metastatic breast cancer burden traces to tumor biology and how much to access to care, in a 2025 study. The team drew on a North Carolina population cohort of nearly three thousand patients diagnosed between 2008 and 2013, followed for twelve years. Tumor data came from records and gene expression; access data came from surveys.
About fifteen percent developed metastatic disease, either at diagnosis or as a later recurrence. Aggressive biology mattered greatly: high grade, a LumB subtype, and high recurrence scores each raised the odds several-fold. So did social position: Black race, poverty, and low education each carried higher risk. Accounting for screening, regular care, treatment delays, and community resources softened the poverty and education links but barely moved the race link. The authors conclude that cutting the burden in Black women requires attacking biology and access together.
Catalog record
| CREATOR | Matthew R. Dunn, Sarah C. Van Alsten, Marc A. Emerson, Katherine Reeder-Hayes, Terry Hyslop, Melissa A. Troester |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |